44
Participants
Start Date
December 20, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
Niraparib
200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
RECRUITING
CHU - Angers, Angers
RECRUITING
Centre Hospitalier d'Avignon, Avignon
RECRUITING
Caen - CHU, Caen
NOT_YET_RECRUITING
Lyon - Centre Léon Bérard, Lyon
RECRUITING
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola
NOT_YET_RECRUITING
Instituto Europeo di Oncologia (IEO), Milan
NOT_YET_RECRUITING
Santa Maria della Misericordia Hospital, Perugia
NOT_YET_RECRUITING
AULSS2 Marca Trevigiana Treviso, Treviso
NOT_YET_RECRUITING
Complejo Hospitalario Universitario a Coruña, A Coruña
RECRUITING
Complejo Hospitalario de Jaén, Jaén
RECRUITING
Hospital Universitario Puerta de Hierro, Madrid
RECRUITING
Kantonsspital Baden, Baden
RECRUITING
University Hospital Basel, Basel
RECRUITING
Inselspital Bern, Bern
RECRUITING
Kantonsspital St. Gallen, Sankt Gallen
RECRUITING
Centre Hospitalier du Valais Romand, Sion
RECRUITING
Bürgerspital Solothurn, Solothurn
RECRUITING
Kantonsspital Winterthur, Winterthur
Collaborators (2)
GlaxoSmithKline
INDUSTRY
Development Limited
UNKNOWN
ETOP IBCSG Partners Foundation
NETWORK